China
The firm, which has also hired a senior trademark leader to lead operations in the region, believes greater China to be one of the most important IP jurisdictions
In the final part of a series on challenging patent invalidation decisions in China, lawyers at Spruson & Ferguson and Marshall Gerstein share how courts adjudicate appeals
Newly independent King & Wood has established offices in North America, while Mallesons has entered a ‘new era’ with a 1,200-lawyer firm across Australia and Singapore
In the first of a two-part article, lawyers at Spruson & Ferguson and Marshall Gerstein provide an overview of China’s system for appealing against patent invalidation decisions
Sponsored
Sponsored
-
Sponsored by CCPIT Patent and Trademark Law OfficeHongxia Wu of CCPIT Patent and Trademark Law Office outlines the potential impact of the 2025 amendments on overseas companies operating in the country -
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical formulation patents
-
Sponsored by Liu, Shen & AssociatesWenjing Zhu of Liu, Shen & Associates explains how China’s administrative adjudication system is reshaping patent enforcement, offering faster, cost-effective, and technically expert resolutions for patentees, while preserving rights to pursue court remedies
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions, with key CNIPA decisions clarifying the treatment of dosage regimens and patient subgroups in novelty determinations
-
Sponsored by Liu, Shen & AssociatesHongbo Jia of Liu, Shen & Associates examines recent Supreme People’s Court cases that reshape Chinese patent litigation in addressing damages, patent validity, and pre-litigation injunctions, with important implications for multinational businesses
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry
